LONDON – Immatics Biotechnologies GmbH signed up Roche AG in a wide-ranging collaboration that boasts a headline value of $1 billion and ushers the company’s cancer immunotherapy platform into the pharmaceutical mainstream. Roche is taking rights to an existing gastric cancer vaccine, IMA942, and will take the product into Phase I development in-house.